Form 4: ADMA Biologics Director Exercises Options and Sells Shares for Significant Gain

ADMA Biologics Director Jerrold B. Grossman exercised stock options and simultaneously sold an equal number of shares on June 9, 2025, realizing a substantial profit.

Summary

• Director Jerrold B. Grossman exercised options to acquire 10,000 shares of ADMA Biologics common stock at an exercise price of $5.00 per share on June 9, 2025.
• Concurrently, Mr. Grossman sold 10,000 shares of ADMA Biologics common stock at a weighted average price of $21.31 per share, with individual transactions ranging from $21.29 to $21.35.
• Following these transactions, Mr. Grossman directly owns 478,194 shares, which includes 10,889 restricted stock units granted on February 19, 2025, vesting on February 19, 2026.
• He also maintains indirect beneficial ownership of 22,857 shares through Brookwood LLC, 31,381 shares through the Jerrold Grossman 2019 Irrevocable Trust, 38,294 shares through Genesis Foundation Inc., and 175 shares through his wife.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine insider monetization of options, indicating a significant personal gain for the director due to stock appreciation. While a sale might be viewed with slight caution, it is often part of a pre-planned strategy or for tax purposes, and the underlying stock performance that enabled the gain is positive.

Positives

• The sale price of $21.31 per share is significantly higher than the exercise price of $5.00, indicating a substantial profit of $16.31 per share for the director on the exercised options, reflecting appreciation in ADMA Biologics' stock value.

Negatives

• The sale of shares by a director, even if part of a pre-planned or cashless exercise, reduces the insider's direct equity stake in the company, which some investors might interpret as a slight reduction in insider conviction.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook or operational performance.

Industry Context

This filing is a routine insider transaction report (Form 4) for ADMA Biologics, a company operating in the biotechnology and pharmaceutical sector. Such transactions are common for executives and directors managing their equity compensation and personal portfolios. The specific transaction, an option exercise followed by a sale, is a frequent strategy for insiders to realize value from vested options, often referred to as a 'cashless exercise' or 'sell-to-cover' to manage tax obligations or diversify holdings. It does not inherently reflect a change in the company's strategic direction or competitive position within the industry.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures across all industries for reporting insider transactions, ensuring transparency in executive stock movements.
• The specific transaction type (exercise and sell) is a common practice for executives in publicly traded companies, including those in the biotechnology sector, to monetize equity compensation.
• Without specific financial performance data for ADMA Biologics or its peers in this document, a direct comparison of operational results or valuation metrics to industry benchmarks is not possible.
• However, the significant difference between the exercise price ($5.00) and the sale price ($21.31) indicates a substantial gain for the director, which is typical for long-held, in-the-money options in a company with appreciating stock value, aligning with successful equity compensation outcomes seen across various industries.

Related Party Transactions

• The reporting person indirectly owns shares through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, which are considered related party holdings as disclosed in the footnotes.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways, from routine portfolio management to a signal about future prospects. However, the context of an option exercise suggests a monetization event rather than a lack of confidence. The significant profit realized by the director from the options could be seen positively as it reflects stock appreciation.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The remaining 10,889 restricted stock units held directly by the reporting person are scheduled to vest in full on February 19, 2026, subject to continued service.

Key Dates

Recommendation

Keywords

ADMA Biologics, ADMA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Jerrold B. Grossman, Beneficial Ownership